To bring scientists, executives and other biopharmaceutical professionals from the Pacific Rim countries together to discuss the latest advances in the biotechnology/pharmaceutical world, the unprecedented challenges and promises facing the industry, and the breathtaking developments and opportunities in Asia/Pacific countries.
- The BioPacific Conference is the annual flagship event of the CABS. Our mission is to bring scientists, executives and biopharmaceutical professionals from the Pacific Rim countries together to discuss the latest advances in the world of life sciences, the unprecedented challenges and promises facing the industry, and the breathtaking developments and opportunities in Asia/Pacific countries.
BioPacific Conference 2019 (aka 20th Annual Conference of CABS, Chinese- American BioPharmaceutical Society), will be held on June 22th, 2019 in the San Mateo Marriott San Francisco Airport, 1770 South Amphlett Blvd, San Mateo, CA 94402. This full-day event is expected to attract over 600+ attendees of life science professionals from the great San Francisco Bay Area.
Date and Time: June 22th, 2019 @ 8:00 am – @ 7:00 pm
Location: San Mateo Marriott San Francisco Airport, 1770 South Amphlett Blvd, San Mateo, CA 94402
The theme of the BioPacific Conference 2019 will be “Pursuing Science for Cure”
- 10 years growth story of BeiGene: how the leading Chinese biotech achieved 7 billion of market cap
- Cure HIV: Gilead’s next battle after its success in HCV
- Denali’s new approaches for neurodegenerative disease
- Discovery story behind Talazoparib: 2018 approved therapeutics for breast cancer
- The recent advances in cancer biomarker and precision medicine
- Next wave of cancer therapies and combinations
- The latest foreign investment regulation and policy
|
2019 CONFERENCE SPEAKERS
|
|
|---|---|
 |
Ron Mazumder, PhD, VP, Global Head of Oncology Biomarker. Keynote: Biomakers and Translational Research in Cancer Therapy |
 |
Jason Liu, PhD, MBA, CEO, WuXi Diagnostics. New Diagnostics Ecosystem to Accelerate Drug Discovery and Medical Innovation |
 |
John V. Oyler, Founder, CEO and Chairman CABS 2019 K. Fong Awardee Speech. The Future of the Biopharma Industry: Innovation Beyond Science |
 |
Romas Geleziunas, PhD, Executive Director, Biology Designing Therapies to Cure HIV |
 |
Joseph Benkert, Senior Advisor, National Security Group. Key Developments: CFIUS, Export Control Reform, and Recent Decisions Affectiong Life Sciences Investment and Licensing |
 |
Zachary Sweeney, PhD, Head of Therapeutic Discovery. New Approaches To Neurodegenerative Disease Drug Discovery and Development |
 |
Shivaani Kummar, MD, Professor of Medicine. Applying Precision Medicine One Patient at a Time |
 |
Leonard Post, PhD, CSO. Talazoparib: From Virtual Drug Discovery to FDA Approval |
| and more | |
